“ ... including a potential regulatory path forw
Post# of 148292
(Total Views: 429)
Posted On: 10/15/2020 11:41:13 PM
“ ... including a potential regulatory path forward.”
Management will discuss the recommendations of the Data Safety Monitoring Committee (DSMC) following their review of the interim analysis of the first 195 patients enrolled in the Company’s Phase 2b/3 clinical trial for patients with severe-to-critical COVID-19 indications, including a potential regulatory path forward.
Management will discuss the recommendations of the Data Safety Monitoring Committee (DSMC) following their review of the interim analysis of the first 195 patients enrolled in the Company’s Phase 2b/3 clinical trial for patients with severe-to-critical COVID-19 indications, including a potential regulatory path forward.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼